Filing Scope and Business Context
Important discrepancy: The supplied filing is for Olivia Ventures, Inc., not Compass Therapeutics, Inc. It is a Form 10-K for the fiscal year ended March 31, 2019, filed July 1, 2019; it does not present 2018 Q4 results for Compass Therapeutics.
Olivia Ventures was incorporated on March 20, 2018, and operated as a blank-check and shell company seeking a business combination. It had no operating business, employees, identified target, definitive acquisition agreement, or revenue-generating activities.
Financial Performance and Condition
| Metric | Fiscal year ended March 31, 2019 | Comparable period |
|---|---|---|
| Revenue | $0 | $0 for the period from inception to March 31, 2018 |
| Net loss | $36,037 | $35,052 |
| Loss per share | $0.01 basic and diluted loss | $0.01 basic and diluted loss |
| Cash from operating activities | $(32,759) | $(35,000) |
| Cash from financing activities | $37,625 | $35,000 |
| Cash | $4,866 | $0 |
| Total assets | $4,866 | $25 |
| Total current liabilities | $75,455 | $34,577 |
| Stockholders’ deficit | $(70,589) | $(34,552) |
Expenses consisted primarily of legal, accounting, audit, other professional fees, general and administrative costs, and interest expense of $3,278. Margins are not meaningful because the company had no revenue. The company had no material off-balance-sheet arrangements.
The related-party promissory note payable to director and stockholder Mark Tompkins had a principal balance of $72,125 and accrued interest of $3,330 at March 31, 2019, for a total amount due of $75,455. The note bears interest at 6% annually and becomes subject to an 18% default rate beginning five days after an event of default.
Material Changes Versus the Prior Comparable Period
- Net loss increased from $35,052 to $36,037, primarily reflecting a full fiscal year of expenses versus approximately 12 days of activity in the prior period.
- Cash increased from $0 to $4,866, supported by $37,600 of additional related-party borrowings and collection of a $25 stock subscription receivable.
- Total liabilities increased from $34,577 to $75,455, principally because of additional advances under the related-party note.
- Accumulated deficit increased from $35,052 to $71,089, resulting in a stockholders’ deficit of $70,589.
- The company remained a shell company and did not identify or execute a business combination.
Outlook, Risks, and Unusual Items
Management planned to continue searching for an acquisition candidate and expected to incur reporting, investigation, due diligence, and transaction costs. No specific milestones or completion timeline had been established, and no acquisition target had been identified.
The independent auditor highlighted substantial doubt about the company’s ability to continue as a going concern because of recurring losses, negative working capital, and stockholders’ deficit. Management expected to rely on additional borrowings under the existing note, equity financing through a potential reverse merger, or other related-party funding, but there was no obligation for stockholders or management to provide additional funds.
- Any future business combination could cause substantial dilution to existing stockholders and may result in current stockholders losing voting control.
- The company faced significant competition from better-capitalized entities seeking business combinations.
- Management had outside business activities and expected to devote limited time to Olivia Ventures before identifying a target.
- Potential conflicts of interest existed because management was affiliated with other blank-check companies and Montrose Capital.
- The company had no dividend history and did not expect to pay dividends before a business combination.
- The company elected JOBS Act extended accounting-transition provisions, which may reduce comparability with public companies using public-company adoption dates.
Investor Verification Priorities
- Verify the issuer and period: the supplied document is Olivia Ventures’ fiscal 2019 Form 10-K, not a Compass Therapeutics filing or a 2018 Q4 report.
- Verify the going-concern qualification and the company’s ability to fund operations with only $4,866 of cash.
- Review the $75,455 related-party note payable, including its repayment trigger, interest terms, and default provisions.
- Confirm that no target business, definitive agreement, or business-combination timeline existed as of the filing.
- Assess potential dilution, changes in control, and conflicts arising from a future reverse merger or acquisition.
- Confirm ownership concentration: Mark Tompkins held 95% and Ian Jacobs held 5% of the 5,000,000 outstanding common shares.